Patient Square Capital LP Increases Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Patient Square Capital LP grew its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 147.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 224,038 shares of the company's stock after buying an additional 133,466 shares during the period. Enliven Therapeutics accounts for approximately 1.9% of Patient Square Capital LP's investment portfolio, making the stock its 8th largest holding. Patient Square Capital LP owned approximately 0.46% of Enliven Therapeutics worth $5,041,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its holdings in Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after purchasing an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in Enliven Therapeutics in the fourth quarter valued at approximately $97,000. BNP Paribas Financial Markets acquired a new stake in Enliven Therapeutics during the 4th quarter worth $112,000. ExodusPoint Capital Management LP bought a new stake in shares of Enliven Therapeutics during the 4th quarter valued at $200,000. Finally, Brevan Howard Capital Management LP acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at $228,000. Institutional investors own 95.08% of the company's stock.

Insiders Place Their Bets

In related news, CEO Samuel Kintz sold 12,500 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the sale, the chief executive officer now directly owns 990,392 shares in the company, valued at $20,629,865.36. This trade represents a 1.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Anish Patel sold 6,667 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $21.44, for a total transaction of $142,940.48. Following the completion of the sale, the chief operating officer now directly owns 323,310 shares in the company, valued at $6,931,766.40. This represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 76,111 shares of company stock worth $1,493,145. Corporate insiders own 29.20% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright lifted their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research note on Friday, March 21st.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock opened at $20.03 on Wednesday. The firm has a market capitalization of $982.79 million, a price-to-earnings ratio of -10.54 and a beta of 1.07. The company's 50 day simple moving average is $18.99 and its 200 day simple moving average is $21.91. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The firm had revenue of $0.03 million during the quarter. As a group, analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Want to see what other hedge funds are holding ELVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.